Thirty-nine children
cm/year in the 3rd year. HV SDS for CA and HV SDS for BA were also improved in the 1st year of GH treatment, but they declined progressively during the subsequent years (Figs. 2 and 3). There was no difference in BA advancement (A BA) during GH therapy (Fig. 4) . There was no overweight nor adverse effect during GH therapy.
Discussion
In this study, 15 out of 39 patients (38 %) had impaired GH secretion. Four of them had asphyxia at birth or prolonged jaundice. Impaired GH secretion has been found in some cases of Noonan syndrome (4-7). The exact causes of impaired GH secretion in Noonan syndrome are not known. GH therapy indeed promotes height velocity and may improve final height for Turner syndrome (3). This has led to the acceptance of GH therapy for Turner syndrome in clinical practice in several countries. The similarity of Noonan syndrome to Turner syndrome led to the expectation that GH treatment may have a beneficial effect. There are several reports on GH therapy in Noonan syndrome but none on the effect of long-term GH therapy on final height (4-7). The efficacy of short-term GH therapy has been reported. Otten (4) investigated 55 patients with Noonan syndrome treated with GH enrolled in the Kabi International Growth Study (KIGS). The median GH dose was 0.6 IU/kg/week with a median frequency of six injections per week. The mean pre-treat- Noonan syndrome with GH in a dose regimen of 0.12 to 0.18 IU/kg/day as a daily subcutaneous injection. After one year of treatment, height velocity SDS increased from a mean of -2.1 to a mean of +3.1 and after two years of 
